Valneva SE
Update in progressVALN (NasdaqGS)
- Company RatingNeutralCompany RatingCombines sentiment and sustainability signals into an overall assessment of the company.Great · Good · Neutral · At Risk · Poor
- SectorHealthcare
- IndustryBiotechnology
Valneva SE is a specialty vaccine company that develops, manufactures, and commercializes vaccines for unmet infectious disease needs. Its products include IXIARO (Japanese encephalitis), DUKORAL (cholera/ETEC diarrhea), and IXCHIQ/VLA1553 (chikungunya). It also advances VLA15 (Lyme risk), S4V2 (shigellosis), VLA1601 (Zika), VLA1554 (hMPV), VLA84 (C. difficile), and VLA2112 (EBV). Markets include the US, Canada, Europe, and beyond. Founded in 1998, based in Saint-Herblain, France.
Company score
- Sentiment
- -0.52
- SentimentMeasures the overall tone of recent coverage and discussion about the company.−10 negative · 0 neutral · +10 positive
- Environment
- 0.00
- EnvironmentAssesses the company’s environmental impact, risks, and sustainability practices.−10 negative · 0 neutral · +10 positive
- Social
- -0.62
- Governance
- -0.61
- GovernanceAssesses leadership, accountability, transparency, and business ethics.−10 negative · 0 neutral · +10 positive
- Sustainability
- -0.31
- SustainabilityCombines environmental, social, and governance signals into an overall sustainability score.−10 negative · 0 neutral · +10 positive
- Impact Score
- -0.42
- Impact ScoreCombines sentiment and sustainability performance into an assessment of the company’s overall impact.−10 negative · 0 neutral · +10 positive
Sort by
Order by
Timeframe
No news articles are available for this company yet.
Unable to load company news.
Loading more news
You're all caught up!